Neurogene Inc. (NASDAQ: NGNE), a biotechnology company based in New York, has announced the appointment of Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to its Board of Directors. Shafer, who has over 20 years of experience in the industry, will be responsible for leading the commercial strategy and launch readiness for NGN-401, a gene therapy targeting Rett syndrome. She previously held senior roles at Avidity Biosciences and Marinus Pharmaceuticals, where she successfully launched therapies for rare neurological diseases. Mikail, who is currently the President and CFO of Neurogene, will enhance the Board's strategic and operational leadership as the company advances its key priorities. Her expertise in strategic transactions and corporate development is expected to support Neurogene's long-term growth objectives. Both appointments come at a crucial time as Neurogene prepares for the potential commercialization of NGN-401, which represents a significant opportunity to improve outcomes for patients suffering from devastating neurological conditions.